Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/8/2013

of 2012.  Common shares used in calculating basic and diluted earnings per share were 37,133,358 for the first quarter of 2013 compared to 19,607,483 for the first quarter of 2012.

During the first quarters of 2013 and 2012, AcelRx recognized revenue of $940,000 and $329,000, respectively, resulting from reimbursement for work completed under a research grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC, for development of ARX-04, a sufentanil NanoTab product candidate for the treatment of moderate-to-severe acute pain in a range of ambulatory environments.Research and development, or R&D, expenses for the quarter ended March 31, 2013 totaled $9.3 million, compared with $4.8 million for the quarter ended March 31, 2012.  The increase was primarily due to expense associated with Phase 3 clinical studies of the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain, and Phase 2 study expenses for the single-dose sufentanil NanoTab product candidate, ARX-04.General and administrative expenses were $2.2 million for the first quarter of 2013, compared with $2.1 million for the quarter ended March 31, 2012.Other income and expense includes a $1.8 million non-cash charge in the first quarter of 2013 resulting from the liability accounting related to the warrants issued in connection with the PIPE financing completed in June 2012.  The primary determinant of this charge was an increase in stock price during the first quarter of 2013 and its resulting impact on the Black-Scholes valuation of these warrants.

As of March 31, 2013, AcelRx had cash, cash equivalents and investments of $48.2 million, compared to $59.8 million at December 31, 2012.

Review of Recent Accomplishments and Corporate Update

  • On March 5, 2013, AcelRx announced positive top-line results from the first of two pivotal Phase 3 double-blind, placebo-controlled efficacy and safety clinica
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
    2. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
    3. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
    4. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
    5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
    6. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
    7. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
    8. AcelRx Pharmaceuticals Provides Clinical Trial Updates
    9. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
    10. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
    (Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
    (Date:10/20/2014)... Lpath, Inc. (NASDAQ: LPTN ... official notification from the European Patent Office that ... supporting its iSONEP™ and ASONEP™ programs. ... 2087002, claims compositions of matter related to sonepcizumab, ... iSONEP and ASONEP. Sonepcizumab is an antibody that ...
    Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
    (Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
    (Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
    (Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today announced ... module enables easy administration and routing of follow-up items ... This application allows users such as Therapists to assign ... item to a specific client, categorize tasks the way ... for follow-ups. It's designed to enable easy access ...
    (Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
    (Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
    Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
    ... variations that point to spectrum disorders , TUESDAY, March ... for brain proteins that seem to be linked to ... of the most comprehensive genetic analyses of association between ... spectrum disorder] risk," said Anthony Monaco, of the Wellcome ...
    ... ... Detox Protocol using Far Infrared. FIR therapy is a major key for returning us back ... ... Ph.D., RIET-1, a Doctor of Integrative Medicine and an Industrial Toxicologist, has dedicated a ...
    ... complications, costs, , TUESDAY, March 30 (HealthDay News) -- Current ... age 45, especially for those who are overweight, but new ... 30 and 45 for everyone . , When screening ... every year to five years, the average cost per quality-adjusted ...
    ... lung cancer per year in Germany are due to ... in the current edition of Deutsches rzteblatt International ... and his coauthors ( Dtsch Arztebl Int 2010; ... the results of relevant studies, the recently published S1 ...
    ... One in three South Asian, West Asian or Arab women ... say they have trouble accessing a doctor to address ... findings, from a new study by researchers at St. Michael,s ... finds this group and immigrant women and men are at ...
    ... ... Misunderstandings about proper use of antibiotics have the potential to ... report in the April issue of AJIC: American Journal of Infection ... Control and Epidemiology, Inc. (APIC). esearchers from Columbia University and MixedInk ...
    Cached Medicine News:Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 3Health News:Diabetes Screening Should Start Sooner 2Health News:Diabetes Screening Should Start Sooner 3Health News:Minority women least likely to gain access to a doctor, study says 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 3Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 4Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 5
    ... automated, random access immunoassay ... assays available worldwide. thyroid, ... therapeutic drug, serology, anemia ... be performed on a ...
    ... The Dimension Xpand integrated chemistry ... very compact footprint to the ... innovation and integration, the Dimension ... state-of-the-art Dimension technology, specifically tailored ...
    ... integrated systems combine the ease of use ... of the Multiply and Quicklyte integrated multisensors ... to meet the challenges of your laboratory. ... the systems can meet over 97% of ...
    ... SkanWasher 400 is an ... washer with built-in pressure ... individual pressure settings allow ... gentle wash to a ...
    Medicine Products: